Eyestem

NEWS DESK

Eyestem Receives CDSCO Approval to Initiate Phase 2 Randomized, Controlled Human Trials of Eyecyte-RPE™

News Desk 28/01/2026

Eyestem Research Pvt Ltd, a pioneering biotechnology company developing advanced scalable cell therapy solutions for blindness caused by dry age-related macular degeneration, has received approval from the Central Drugs Standard Control Organisation (CDSCO) to initiate the clinical trial of its

NEWS DESK

Eyestem’s Dr. Jogin Desai Presents Landmark Phase 1 Results of Eyecyte-RPE™ Trial at Innoxbio CGT 2025 in Guangzhou, China

News Desk 13/11/2025

Eyestem Research Pvt. Ltd., a clinical-stage biotechnology company pioneering scalable cell therapy solutions for retinal diseases, announced the successful presentation of its groundbreaking phase one clinical trial results at the 3rd China Great Bay Cell and Gene Therapy Forum (Innoxbio CGT 2025), held on November 12–13, 2025, in Guangzhou Knowledge City. Innoxbio China

NEWS DESK

Eyestem Raises Funds to Advance Eyecyte-RPE™ Through Phase 2 Clinical Trial and Towards US IND

PR News Desk 11/08/2025

Eyestem Research Pvt Ltd has raised funds in a significantly oversubscribed funding round to support the next stage of development for its investigational retinal pigment epithelial (RPE) cell therapy, Eyecyte-RPE™. The capital will enable completion of the ongoing Phase 2 clinical trial in India and support preparations for filing an Investigational New Drug (IND)

NEWS DESK

Eyestem Announces Completion of Phase One of its RPE Cell Therapy With Promising Efficacy and Safety Outcomes

PR News Desk 18/06/2025

Eyestem Research Pvt Ltd announced the completion of its phase one study for its investigational retinal pigment epithelium (RPE) cell therapy, Eyecyte-RPE. The clinical study report of the study has been submitted to the Central Drugs Standard Control Organisation (CDSCO) for permission to start the phase 2 study. The trial, designed to evaluate the safety […]